Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research report report published on Saturday morning.

Several other analysts have also recently weighed in on the company. Bank of America reduced their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $40.67 on Friday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -5.81 and a beta of 0.89. The company has a 50 day simple moving average of $39.77 and a 200 day simple moving average of $36.27. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. During the same quarter last year, the business posted $16.22 EPS. Agios Pharmaceuticals’s revenue for the quarter was up 43.3% on a year-over-year basis. On average, equities research analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at $2,711,049.84. The trade was a 5.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the sale, the chief financial officer owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,899 shares of company stock worth $611,324 over the last three months. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at $45,000. CWM LLC boosted its stake in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 996 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 499 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.